A Randomized, Double Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of Intravenous Dihydroergotamine (DHE) and Orally Inhaled DHE (MAP0004) on Pulmonary Arterial Pressure and Tolerability in Healthy Adults

Trial Profile

A Randomized, Double Blind, Placebo Controlled, Three-Period Crossover Study Comparing the Acute Effects of Intravenous Dihydroergotamine (DHE) and Orally Inhaled DHE (MAP0004) on Pulmonary Arterial Pressure and Tolerability in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2014

At a glance

  • Drugs Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary) ; Dihydroergotamine mesilate (Primary)
  • Indications Migraine
  • Focus Pharmacodynamics; Registrational
  • Sponsors Allergan
  • Most Recent Events

    • 05 Jun 2011 Results presented at the 53rd Annual Scientific Meeting of the American Headache Society.
    • 16 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
    • 28 Feb 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology (AAN).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top